Insider Buying: TherapeuticsMD Inc (NASDAQ:TXMD) Insider Purchases $29,300.00 in Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $2.93 per share, for a total transaction of $29,300.00. Following the purchase, the insider now owns 1,472,419 shares in the company, valued at approximately $4,314,187.67. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

John C.K. Iv Milligan also recently made the following trade(s):

  • On Monday, August 12th, John C.K. Iv Milligan purchased 15,000 shares of TherapeuticsMD stock. The stock was acquired at an average price of $3.16 per share, for a total transaction of $47,400.00.

NASDAQ TXMD opened at $2.78 on Thursday. The business’s 50-day moving average price is $2.49 and its two-hundred day moving average price is $3.85. TherapeuticsMD Inc has a 12 month low of $1.82 and a 12 month high of $6.94. The firm has a market capitalization of $680.25 million, a PE ratio of -4.71 and a beta of 1.90. The company has a current ratio of 5.17, a quick ratio of 4.99 and a debt-to-equity ratio of 24.29.



TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The company had revenue of $6.08 million during the quarter, compared to the consensus estimate of $5.12 million. During the same quarter last year, the firm posted ($0.15) EPS. The company’s quarterly revenue was up 60.0% on a year-over-year basis. As a group, analysts forecast that TherapeuticsMD Inc will post -0.73 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on TXMD shares. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Noble Financial restated a “buy” rating and set a $13.00 price objective on shares of TherapeuticsMD in a research report on Monday, August 12th. ValuEngine upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. reduced their price objective on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, June 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $9.28.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Frontier Capital Management Co. LLC lifted its stake in shares of TherapeuticsMD by 291.5% in the 1st quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after purchasing an additional 4,360,963 shares during the period. Rubric Capital Management LP raised its stake in TherapeuticsMD by 203.6% during the 1st quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock worth $22,845,000 after buying an additional 3,145,742 shares during the period. SG Americas Securities LLC raised its stake in TherapeuticsMD by 470.5% during the 2nd quarter. SG Americas Securities LLC now owns 2,804,571 shares of the company’s stock worth $7,292,000 after buying an additional 2,312,933 shares during the period. C WorldWide Group Holding A S increased its holdings in TherapeuticsMD by 222.3% during the 2nd quarter. C WorldWide Group Holding A S now owns 3,189,834 shares of the company’s stock worth $8,294,000 after purchasing an additional 2,200,000 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in TherapeuticsMD by 3,177.6% during the 2nd quarter. Invesco Ltd. now owns 2,155,247 shares of the company’s stock worth $5,603,000 after purchasing an additional 2,089,491 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

See Also: What are municipal bonds?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.